1206630-22-9

Basic information

• Product Name: 5-bromo-2-(diethoxymethyl)-1,3-difluorobenzene
• Synonyms: 5-bromo-2-(diethoxymethyl)-1,3-difluorobenzene
• CAS NO: 1206630-22-9
• Molecular Weight: 295.124
• Mol File: 1206630-22-9.mol

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-(diethoxymethyl)-1,3-difluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(diethoxymethyl)-1,3-difluorobenzene(1206630-22-9)
• EPA Substance Registry System: 5-bromo-2-(diethoxymethyl)-1,3-difluorobenzene(1206630-22-9)

Safety Data

• Hazardous Substances Data: 1206630-22-9(Hazardous Substances Data)

Upstream product

• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 122-51-0 orthoformic acid triethyl ester 
• 461-96-1 3,5-difluorobromobenzene 

Downstream Products

• 1206630-23-0 2-[4-(diethoxymethyl)-3, 5-difluorophenyl]propan-2-ol 
• 1639042-39-9 methyl (2E)-3-(3,5-difluoro-4-formylphenyl)prop-2-enoate 

Relevant articles and documents

Efficient Manufacturing Process for the Selective Estrogen Receptor Degrader GDC-9545 (Giredestrant) via a Crystallization-Driven Diastereoselective Pictet-Spengler Condensation

GDC-9545 is a selective estrogen receptor degrader that is being developed as a treatment for ER+/HER2- breast cancer. A robust, convergent manufacturing process for GDC-9545 was developed. The process features a Wenker aziridine synthesis to produce the key starting material tryptamine 11, a highly efficient C-N coupling between aminoazetidine 9 and 2,6-difluoro-4-bromobenzaldehyde diethyl acetal (33) to construct key intermediate 10, and a crystallization-driven diastereoselective Pictet-Spengler reaction to furnish the active pharmaceutical ingredient GDC-9545·tartrate.

Synthesis method of (E)-methyl ester 3-(3,5-difluoro-4-formyl phenyl)acrylic acid

The invention provides a synthesis method of (E)-methyl ester 3-(3,5-difluoro-4-formyl phenyl)acrylic acid, and relates to the field of organic synthesis. The method comprises the following steps: (1) aldehyde group protection: reacting a compound 1, ammonium chloride and alcohol to obtain a compound 2, wherein the alcohol is selected from monohydric alcohol or dihydric alcohol; (2) introducing formyl: reacting the compound 2 serving as a raw material with an organic metal reagent in an organic solvent, and then adding N,N-dimethylformamide for reaction to obtain a compound 3; (3) Wittig-Horner reaction: adding alkali and a compound containing a phosphonate group into the compound 3, and reacting to obtain a compound 4; and (4) deprotection reaction: adding a compound containing a sulfonic acid group and water into the compound 4, and reacting to obtain the product. The synthesis method does not use a noble metal catalyst, so that the cost is obviously reduced; and the product prepared by the synthesis method is high in yield, high in purity, environment-friendly, high in safety and suitable for industrial production, and has a good application prospect.

SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE

Provided herein are solid forms, salts such as compound B, and formulations of 3-((lR,3R)-l-(2,6-difluoro-4-((l-(3-fluoropropyl) azetidin-3-yl)amino)phenyl)-3-methyl-l,3,4,9-tetrahydro-2H- pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-l-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.

TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

INHIBITORS OF JANUS KINASES

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.